NCT03225716 2024-05-03A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaDana-Farber Cancer InstitutePhase 1 Terminated13 enrolled 13 charts
NCT01120457 2015-03-06First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersBristol-Myers SquibbPhase 1 Completed96 enrolled